Table 2.

Demographics and characteristics of patients included in the all-exposed cohort

Patient characteristics	Placebo (n = 802)	Cladribine (n = 1976)
Female, n (%)	535 (66.7)	1306 (66.1)
Time on study in weeks, mean (SD)	180.99 (135.03)	260.23 (139.20)
Patient-years of exposure	2782	9855
Age at clinical study baseline (years), mean (SD)	37.6 (9.8)	37.7 (10.1)
Median	37.0	38.0
Minimum; maximum	18; 64	18; 65
Age ≤ 40 years, n (%)	485 (60.5)	1162 (58.8)
Prior treatment with DMD, n (%)	188 (23.4)	505 (25.6)
Disease duration in years, mean (SD)	9.50 (7.44)	8.91 (7.21)

DMD disease-modifying drug, SD standard deviation